943606-85-7

Basic information

• Product Name: 6-Methyl-5-nitroisoquinolin-1(2H)-one
• Synonyms: 6-Methyl-5-nitroisoquinolin-1(2H)-one;6-Methyl-5-nitroisoquinolin-1-ol
• CAS NO: 943606-85-7
• Molecular Formula: C10H8N2O3
• Molecular Weight: 204.18212
• Mol File: 943606-85-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Methyl-5-nitroisoquinolin-1(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Methyl-5-nitroisoquinolin-1(2H)-one(943606-85-7)
• EPA Substance Registry System: 6-Methyl-5-nitroisoquinolin-1(2H)-one(943606-85-7)

Safety Data

• Hazardous Substances Data: 943606-85-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
6-Methyl-5-nitroisoquinolin-1(2H)-one is utilized as a pharmaceutical candidate for its antimicrobial and antiviral properties, making it a valuable asset in the development of treatments for various infectious diseases.
Used in Organic Synthesis:
6-Methyl-5-nitroisoquinolin-1(2H)-one serves as a building block in the synthesis of other organic compounds, contributing to the advancement of organic chemistry and the creation of novel molecules with potential applications.
Used in Drug Development:
6-Methyl-5-nitroisoquinolin-1(2H)-one may be employed in the development of new drugs, leveraging its unique structure and properties to design innovative therapeutic agents.
Used in Materials Science and Chemical Engineering:
6-Methyl-5-nitroisoquinolin-1(2H)-one may also have applications in the field of materials science and chemical engineering, where its properties could be harnessed for a variety of scientific and industrial purposes.

Upstream product

• 104-87-0 4-methyl-benzaldehyde 
• 943606-83-5 6-methyl-5-nitroisoquinoline N-oxide 
• 42398-73-2 6-methylisoquinoline 
• 188121-31-5 6-methyl-5-nitroisoquinoline 
• 943606-84-6 1-chloro-6-methyl-5-nitroisoquinoline 

Downstream Products

• 1093101-59-7 5-(3-(9-(4-methoxybenzyl)-9H-purin-6-yl)pyridin-2-yloxy)-1-chloro-6-methylisoquinoline 
• 1093100-24-3 5-(3-(9H-purin-6-yl)pyridin-2-yloxy)-N-(4-chlorophenyl)-6-methylisoquinolin-1-amine 
• 1093101-58-6 5-(3-(9-(4-methoxybenzyl)-9H-purin-6-yl)pyridin-2-yloxy)-6-methylisoquinolin-1(2H)-one 
• 1093101-60-0 5-(3-(9-(4-methoxybenzyl)-9H-purin-6-yl)pyridin-2-yloxy)-N-(4-chlorophenyl)-6-methylisoquinolin-1-amine 
• 943602-77-5 5-amino-6-methylisoquinolin-1(2H)-one 

Relevant articles and documents

Selective inhibitors of the mutant B-Raf pathway: Discovery of a potent and orally bioavailable aminoisoquinoline

The discovery and optimization of a novel series of aminoisoquinolines as potent, selective, and efficacious inhibitors of the mutant B-Raf pathway is presented. The N-linked pyridylpyrimidine benzamide 2 was identified as a potent, modestly selective inhibitor of the B-Raf enzyme. Replacement of the benzamide with an aminoisoquinoline core significantly improved kinase selectivity and imparted favorable pharmacokinetic properties, leading to the identification of 1 as a potent antitumor agent in xenograft models. 2009 American Chemical Society.

RAF KINASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula (I) wherein each of A1, A2, A3, A4, A5, A6, A7, A8, A9, bond B, X, rings Z1 and Z2, R1 and R3 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have Formula (I) wherein R1 is Formula (II), (III) or (IV) and A1, A2, A3, A4, X, Z, Z', R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.